Question: Did Gevork Minaskanian or Victor Maghakian do more for the pharmaceutical industry?

Context articles: Lists about the pharmaceutical industry
China Pharmaceutical Industry Association
IFPMA Clinical Trials Portal
Pharmaceutical Price Regulation Scheme
Peter Rost (doctor)
Pharmaceutical industry in Pakistan
RAJ Pharma
Gevork Minaskanian
Side Effects (2005 film)
Victor Maghakian

These are Wikipedia lists about the pharmaceutical industry.
 The pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals licensed for use as medications. Pharmaceutical companies are allowed to deal in generic or brand medications and medical devices.
 They are subject to a variety of laws and regulations regarding the production, testing, and marketing of drugs.
The China Pharmaceutical Industry Association (CPIA) was founded in September 1988 and it is a non-governmental, non-profit pharmaceutical industry association in China.
 Its members are mainly from large and medium-sized pharmaceutical corporations, pharmaceutical machinery and medicinal glass packaging companies, regional pharmaceutical industrial associations, pharmaceutical research institutions, designing institutes, universities, colleges and secondary schools of this sector etc.
The IFPMA Clinical Trial Portal is a major pharmaceutical industry initiative designed to increase the transparency of clinical trials by providing a convenient "one-stop-shop" for published clinical trial information.
 It helps to fulfill the commitment made by the research-based pharmaceutical industry in its Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases, issued in January 2005 and updated November 2008.
 This joint statement was developed by the IFPMA, the European Federation of Pharmaceutical Industries and Associations(EFPIA, the Japan Pharmaceutical Manufacturers Association (JPMA), the Pharmaceutical Research and Manufacturers of America (PhRMA) and Canada’s Research-Based Pharmaceutical Companies (R&d), to provide a coherent industry blueprint for improving clinical trial transparency.
The Pharmaceutical Price Regulation Scheme (PPRS) is the mechanism used by the UK Department of Health to ensure that the NHS has access to good quality branded medicines at reasonable prices.
 It involves a non-contractual agreement between the UK Department of Health and The Association of the British Pharmaceutical Industry (ABPI).
 The scheme applies to all branded, licensed medicines available on the NHS.
 The purpose of the scheme is to achieve a balance between reasonable prices for the NHS and a fair return for the pharmaceutical industry.
Peter Rost, M.D. is a former drug marketing executive and is most known for taking public stances critical of the pharmaceutical industry as an "insider" and whistleblower.
 He sued his last two pharmaceutical employers, Wyeth and Pfizer, the latter of which fired him in 2005.
 At Wyeth, he uncovered tax evasion practices, and after informing senior company executives, was transferred from Sweden to a post in New Jersey.
 Rost sued the company, saying that the transfer was a retaliatory demotion, though the company said it was a promotion.
 Rost settled with Wyeth for an undisclosed amount in 2003.
 At Pfizer, Rost filed a "qui tam" suit disclosing off-label marketing of Genotropin at Pharmacia prior to its purchase by Pfizer.
 The U.S. Department of Justice declined to join in Rost's suit as the marketing violations had already been disclosed to the Department by Pfizer.
 Rost was eventually fired by Pfizer, and sued for wrongful dismissal, but this lawsuit was summarily dismissed by the court based on evidence that Pfizer had decided to fire Rost prior to discovery of his whistleblowing activities.
 Since then, Rost has worked outside the pharmaceutical industry, as a public speaker, blogger, writer, and litigation consultant.
The pharmaceutical industry in Pakistan has grown during the last few decades.
 At the time of the independence of Pakistan in 1947, there were few production units in the country.
 Currently Pakistan has more than 800 large volume pharmaceutical formulation units, including those operated by 25 multinationals present in the country.
 The Pakistan Pharmaceutical Industry meets around 90% of the country's demand of finished dosage forms and 4% of Active ingredients. Specialized finished dosage forms such as soft gelatin capsules, parenteral fat emulsions and Metered-dose inhalers continue to be imported.
 There are only a few bulk drug Active ingredient producers and Pakistan mainly depends on imports of bulk drugs for its formulation needs resulting in frequent drug shortages.
 Political disturbances and allegations of under-invoicing add to the uncertainty of imports and clashes with the customs and tax authorities are common.
The Regulatory Affairs Journal Pharma (RAJ Pharma) is an English language international pharmaceutical information and analysis service published by Informa plc.
 First published as a monthly print magazinel in 1992, it includes articles covering worldwide regulatory affairs within the pharmaceutical industry.
 The journal has now developed into an online global business intelligence and analysis service.
 It provides daily news and analysis of developments in regulation of the pharmaceutical industry worldwide, including regulatory agencies and legislation, application requirements and guidelines, patents and intellectual property, research and development, international harmonisation, paediatric legislation, pharmacovigilance and pharmacoeconomics.
Gevork Minaskanian, Ph.D., is a research professor in the Department of Chemistry at Virginia Commonwealth University and Co-founder/Vice President of Synthetic Chemistry at Aderis Pharmaceuticals who was a contributor to the development of rotigotine and Neupro (a transdermalpatch that delivers rotigotine).
 Rotigotine is a drug developed to mimic the actions of dopamine in the brain to help cope with restless legs syndrome and the abnormal movements(dyskinesia) found in Parkinson's disease patients.
 This drug is an alternative to oral medications for treatment of Parkinson's disease, considered by the VCU Department of Chemistry as "an unprecedented medication for the benefit of millions of Parkinson's patient worldwide."
 Minaskanian’s main contribution to Neupro was improving the efficiency of manufacturing rotigotine, thereby making the process commercially viable and enabling patients to afford this important medication.
 Dr. Minaskanian is the inventor and author of over 50 patents and publications in various fields of organic and medicinal chemistry.
 Some of his US patents include patents 5,470,848; 4,801,586; 5,234,959; 5,118,676; and other related research done on rotigotine and Neupro US patent 7,309,497 found in the United States Patent and Trademark Office linked to the penetration enhancers for transdermal delivery of systemic agents.
Side Effects is a 2005 romantic comedy about the pharmaceutical industry, directed by Kathleen Slattery-Moschkau and starring Katherine Heigl as Karly Hert, a pharmaceutical "detailer", who becomes disillusioned with the lack of ethics in the pharmaceutical industry and has tough choices to make.
 The film also stars Lucian McAfee, Dorian DeMichele, Dave Durbin, Temeceka Harris.
 The film's title is a reference to the medical term "side effects".
Victor Maghakian, also known as Captain Victor "Transport" Maghakian (Armenian: Վիգդոր Մաղաքեան ) (December 30, 1915 – August 17, 1977), was an Armenian American member of the United States Marine Corps during World War II.
 Having received over two dozen medals and awards, he is considered one of the most decorated American soldiers of the war.